GNFT NIS2+ validated as scalable non-invasive MASH diagnostics solution
TradingView News says NIS2+ has been validated as a scalable, non-invasive test aimed at unlocking the MASH diagnostic and monitoring market, supported by pharma partnerships.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
GNFT NIS2+ set to transform MASH diagnostics and patient monitoring
TradingView News says GNFT’s NIS2+ is positioned as a scalable, non-invasive solution for MASH diagnostics, validated by independent studies, aimed at enabling patient identification and monitoring.